Given the patient's clinical phenotype, known risk for immune dysregulation with CTLA4 variants, and without other identifiable etiologies for the aplastic anemia, a research-based functional assay was pursued. This evidence concerns the gene CTLA4 and idiopathic aplastic anemia.